Clinical trials: Relapsed Neuroblastoma
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well selumetinib sulfate works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm
- Trial name
- NCT03213691
- Testing
- Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00026312
- Testing
- Aldesleukin, Dinutuximab, Isotretinoin
- Where
- 197 sites in United States, Australia and 3 more
- Volunteers
- 1,449 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
The purpose of this research study is to evaluate a new investigational drug to prevent reoccurrence of neuroblastoma that is in remission. This study drug is called DFMO.
- Trial name
- NCT02395666
- Testing
- DFMO
- Where
- 22 sites in United States
- Volunteers
- 140 people
- Sponsor
- Giselle Sholler
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma
- Trial name
- NCT03213678
- Testing
- Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography
- Where
- 127 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
This phase II trial studies how well lorvotuzumab mertansine works in treating younger patients with Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or…
- Conditions
- Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma
- Trial name
- NCT02452554
- Testing
- Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study
- Where
- 69 sites in United States
- Volunteers
- 62 people
- Sponsor
- Children's Oncology Group
High Risk Neuroblastoma, Recurrent Neuroblastoma
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma
- Trial name
- NCT04751383
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Ganglioneuroblastoma, Recurrent Neuroblastoma
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment.
- Trial name
- NCT01767194
- Testing
- Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 157 sites in United States, Australia and 3 more
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people…
- Trial name
- N2011-01 (NCT02035137)
- Testing
- 131I-MIBG, Vincristine, Irinotecan
- Where
- 14 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Neuroblastoma
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
The purpose of this research study is to evaluate a new investigational drug to treat neuroblastoma. This study drug is called DFMO.
- Trial name
- NCT01059071
- Testing
- DFMO, Etoposide
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Giselle Sholler
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Neuroblastoma
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy…
- Trial name
- NCT03107988
- Testing
- Lorlatinib, Cyclophosphamide, Topotecan
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Neuroblastoma, Medulloblastoma
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
- Trial name
- NCT00601003
- Testing
- Nifurtimox, Cyclophosphamide, Topotecan
- Where
- 15 sites in United States
- Volunteers
- 112 people
- Sponsor
- Giselle Sholler
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
- Trial name
- NCT00309907
- Testing
- etanercept, methylprednisolone
- Where
- 26 sites in United States
- Volunteers
- 39 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are tolerable when given with irinotecan/vincristine on a one week schedule to children and young adults with high-risk refractory/relapsed…
- Trial name
- NCT01313936
- Testing
- Metaiodobenzylguanidine (MIBG)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- GVHD (NCT00408681)
- Testing
- lithium carbonate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Neuroblastoma
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma
The purpose of this study is to test the feasibility (ability to be done) of an experimental test to help plan your cancer treatment.
- Trial name
- NCT01355679
- Testing
- Guided Therapy
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Giselle Sholler